A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong ...

CHICAGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--GE Healthcare is proud to provide cutting-edge molecular imaging solutions that enable and increase access to precision health and theranostics ...

Chicago, Illinois (Embargoed until 3:45 p.m. CDT, Tuesday, June 27, 2023)—By monitoring early-response biomarkers in men undergoing 177 Lu-PSMA prostate cancer treatment, physicians can personalize ...

BARCELONA, Spain ― Using 177 Lu-PSMA (prostate-specific membrane antigen) SPECT to monitor tumor response at week 12 after the third dose of the targeted radioligand 177 Lu-PSMA-617 (Pluctivo, ...

A new scanner that combines imaging techniques lets doctors get a better look into the bodies of prostate cancer patients. After cancer for prostrate cancer, patients often return for follow-up scans ...

U-SPECT 7 CT from MILabs (a Rigaku company) offers unmatched preclinical dynamic and whole-body Single Photon Emission Computed Tomography (SPECT) performance, integrated with diagnostic micro-CT.

At the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2022 Annual Meeting, GE Healthcare proudly showcases cutting-edge solutions spanning the care continuum and enabling theranostics in ...